Abstract Number: 2609 • 2015 ACR/ARHP Annual Meeting
The Measurement of the Skin Autofluorescence As an Indicator of Disease Progression in Rheumatoid Arthritis Patients
Background/Purpose: In course of rheumatoid arthritis (RA) ther is often impaired glucose metabolism, which leads to the development of diabetes mellitus (DM). One of the…Abstract Number: 2610 • 2015 ACR/ARHP Annual Meeting
Real-World Use of Tocilizumab in Rheumatoid Arthritis Patients: Cardiovascular Risk, Concomitant Treatment, and Outcomes over 6 Months of Follow-up
Background/Purpose: Tocilizumab (TCZ) is approved for the treatment of adults with rheumatoid arthritis (RA) either as monotherapy or in combination with disease-modifying antirheumatic drugs (DMARDs).…Abstract Number: 2611 • 2015 ACR/ARHP Annual Meeting
Circulating Monocyte Count Is Significantly Associated with Interstitial Pneumonia in Biologic-Naive Patients with Rheumatoid Arthritis: A Single-Center Prospective Cohort Study (Keio First-Bio Cohort Study)
Background/Purpose : Interstitial pneumonia (IP) is one of the most critical complications in rheumatoid arthritis (RA). Severe IP is developed in zymosan-treated SKG mice, and…Abstract Number: 2612 • 2015 ACR/ARHP Annual Meeting
Impact of a Multibiomarker Disease Activity Score in Patients with Rheumatoid Arthritis Treated in a Real World Setting
Background/Purpose: A number of composite outcome measures have been validated to quantify disease activity in Rheumatoid Arthritis (RA). Few studies have been published on the…Abstract Number: 2613 • 2015 ACR/ARHP Annual Meeting
Patient Reported Physical Capacity Correlates with Phenylalanine Serum Levels in Patients with Early Untreated Rheumatoid Arthritis
Background/Purpose: Lipolysis is increased in rheumatoid arthritis (RA), and lipid-induced insulin resistance coincides with anabolic resistance. Ability to maintain skeletal muscle mass is impaired in…Abstract Number: 2614 • 2015 ACR/ARHP Annual Meeting
Single Academic Center Experience with 14-3-3 Eta in the Evaluation of Inflammatory Arthritis
Background/Purpose: 14-3-3 proteins are chaperonins found in all eukaryotic cells. There are multiple isoforms which are thought to be involved in intracellular signaling and transcription…Abstract Number: 2615 • 2015 ACR/ARHP Annual Meeting
Changes in a Patient-Reported Measure of Physical Function, PF-10a, Are Most Strongly Associated with Changes in the Patient Global Assessment Portion of a Composite Measure of RA Disease Activity
Background/Purpose: A brief patient-reported measure of physical function, the PROMIS PF-10a, is sensitive to changes in disease activity among patients with rheumatoid arthritis (RA). However,…Abstract Number: 2616 • 2015 ACR/ARHP Annual Meeting
Study of Anti-Carbamylated Protein Antibody in the Rheumatoid Patients Who Were Clinically Active and Under Treatment with Biological Dmards
Background/Purpose: A newly discovered anti-carbamylated protein antibody (anti-CarP) is found prior to disease-onset, associates with the conversion towards arthralgia and with a more severe disease…Abstract Number: 2617 • 2015 ACR/ARHP Annual Meeting
Serum 14-3-3eta Protein Elevation in Osteoarthritis Suggests Misclassification or Concurrent Inflammatory Arthritis
Background/Purpose: Tissue distribution of the chaperonin 14-3-3η (eta) is limited to synovial tissue and brain. Synovium releases proinflammatory 14-3-3η into synovial fluid and serum in…Abstract Number: 2618 • 2015 ACR/ARHP Annual Meeting
Methotrexate Dose May Associated with the Frequency of Lymphoproliferative Disorders in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that is characterized by synovitis and the destruction of articular structures of multiple joints. The goal…Abstract Number: 2619 • 2015 ACR/ARHP Annual Meeting
Clinical Usefulness of Periodic Detection of Serum 14-3-3η for Predicting Efficacy of Tocilizumab in RA
Background/Purpose: Serum 14-3-3η is a diagnostic marker for RA. Recent in vitro evidence indicates that it may play a casual role in the pathogenesis of…Abstract Number: 2620 • 2015 ACR/ARHP Annual Meeting
Predictive Value of Anti-Carbamylated Protein Antibodies in Patients with Early Arthritis
Background/Purpose: Anti-carbamylated protein (anti-CarP) antibodies have been described as a new type of autoantibodies specific of patients with rheumatoid arthritis (RA). They seem useful as…Abstract Number: 2621 • 2015 ACR/ARHP Annual Meeting
Characteristics of Histopathology and Clinical Course of 19 Cases That Developed a Lymphoproliferative Disease (LPD) during Methotrexate (MTX) Treatment.
Background/Purpose: We examined the clinical features of the cases after discontinuation or decrease of dosage of MTX in the MTX-LPD.Methods: We retrospectively examined a patient…Abstract Number: 2622 • 2015 ACR/ARHP Annual Meeting
Serum RANKL Levels, Associate with Anti Citrullinated Proteins Antibodies (ACPA) in Early-Untreated Rheumatoid Arthritis and Is Modulated Following Methotrexate
Background/Purpose: Receptor Activator of Nuclear factor Kappa-b Ligand (RANKL) is a key regulator of bone metabolism. Anti-citrullinated (cit) protein antibodies (ACPA) have been suggested to…Abstract Number: 2623 • 2015 ACR/ARHP Annual Meeting
DAS28-ESR and DAS28-CRP Are Not Exchangeable in Daily Clinical Practice: Data from a Large Outpatient Cohort
Background/Purpose: The original DAS28 is based on the erythrocyte sedimentation rate (ESR). An alternative formulation uses the C-reactive protein (CRP). Previous research1,2,3 suggests that in…